Who Are Candidates for Prevention and Treatment for Osteoporosis?

Overview

Journal Osteoporos Int

Specialties Endocrinology
Orthopedics

Date 1997 Jan 1

PMID 9102057

Citations 52

Affiliations

Soon will be listed here.

Citing Articles

Correlations of the Osteoporosis Self-Assessment Tool for Asians (OSTA) and Three Panoramic Indices Using Quantitative Ultrasound (QUS) Bone Densitometry.

Kiswanjaya B, Bachtiar-Iskandar H, Yoshihara A Dent J (Basel). 2023; 11(2).

PMID: 36826179 PMC: 9955170. DOI: 10.3390/dj11020034.

Singh I, Jose V, Patel R, Arora S Indian J Pharmacol. 2021; 53(1):6-12.

PMID: 33975993 PMC: 8216120. DOI: 10.4103/ijp.IJP_346_19.

Short-range UV-LED irradiation in postmenopausal osteoporosis using ovariectomized mice.

Ochiai S, Nishida Y, Higuchi Y, Morita D, Makida K, Seki T Sci Rep. 2021; 11(1):7875.

PMID: 33846386 PMC: 8042119. DOI: 10.1038/s41598-021-86730-0.

Development prospects of curable osteoplastic materials in dentistry and maxillofacial surgery.

Vasilyev A, Kuznetsova V, Bukharova T, Grigoriev T, Zagoskin Y, Korolenkova M Heliyon. 2020; 6(8):e04686.

PMID: 32817899 PMC: 7424217. DOI: 10.1016/j.heliyon.2020.e04686.

Anti-Inflammatory Effects of Adenine Enhance Osteogenesis in the Osteoblast-Like MG-63 Cells.

Chen Y, Chu Y, Tsuang Y, Wu Y, Kuo C, Kuo Y Life (Basel). 2020; 10(7).

PMID: 32707735 PMC: 7399991. DOI: 10.3390/life10070116.

References

Grady D, Rubin S, Petitti D, Fox C, Black D, Ettinger B . Hormone therapy to prevent disease and prolong life in postmenopausal women. Ann Intern Med. 1992; 117(12):1016-37. DOI: 10.7326/0003-4819-117-12-1016. View

Cummings S, Black D, Nevitt M, Browner W, Cauley J, Ensrud K . Bone density at various sites for prediction of hip fractures. The Study of Osteoporotic Fractures Research Group. Lancet. 1993; 341(8837):72-5. DOI: 10.1016/0140-6736(93)92555-8. View

Boyce W, Vessey M . Rising incidence of fracture of the proximal femur. Lancet. 1985; 1(8421):150-1. DOI: 10.1016/s0140-6736(85)91915-4. View

Morrison N, Qi J, Tokita A, Kelly P, Crofts L, Nguyen T . Prediction of bone density from vitamin D receptor alleles. Nature. 1994; 367(6460):284-7. DOI: 10.1038/367284a0. View

Slemenda C, CHRISTIAN J, Williams C, Norton J, JOHNSTON Jr C . Genetic determinants of bone mass in adult women: a reevaluation of the twin model and the potential importance of gene interaction on heritability estimates. J Bone Miner Res. 1991; 6(6):561-7. DOI: 10.1002/jbmr.5650060606. View

. Clinical indications for bone mass measurements. A report from the Scientific Advisory Board of the National Osteoporosis Foundation. J Bone Miner Res. 1989; 4 Suppl 2:1-28. DOI: 10.1002/jbmr.5650040803. View

Morrison N, Yeoman R, Kelly P, Eisman J . Contribution of trans-acting factor alleles to normal physiological variability: vitamin D receptor gene polymorphism and circulating osteocalcin. Proc Natl Acad Sci U S A. 1992; 89(15):6665-9. PMC: 49563. DOI: 10.1073/pnas.89.15.6665. View

Riis B, Hansen M, Jensen A, Overgaard K, Christiansen C . Low bone mass and fast rate of bone loss at menopause: equal risk factors for future fracture: a 15-year follow-up study. Bone. 1996; 19(1):9-12. DOI: 10.1016/8756-3282(96)00102-0. View

Draper M, Flowers D, Huster W, Neild J, Harper K, Arnaud C . A controlled trial of raloxifene (LY139481) HCl: impact on bone turnover and serum lipid profile in healthy postmenopausal women. J Bone Miner Res. 1996; 11(6):835-42. DOI: 10.1002/jbmr.5650110615. View

10.

Riis B, Overgaard K, Christiansen C . Biochemical markers of bone turnover to monitor the bone response to postmenopausal hormone replacement therapy. Osteoporos Int. 1995; 5(4):276-80. DOI: 10.1007/BF01774018. View

11.

Liberman U, Weiss S, Broll J, Minne H, Quan H, Bell N . Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group. N Engl J Med. 1995; 333(22):1437-43. DOI: 10.1056/NEJM199511303332201. View

12.

Riggs B, OFallon W, Lane A, Hodgson S, Wahner H, Muhs J . Clinical trial of fluoride therapy in postmenopausal osteoporotic women: extended observations and additional analysis. J Bone Miner Res. 1994; 9(2):265-75. DOI: 10.1002/jbmr.5650090216. View

13.

Iversen E, Hassager C, Christiansen C . The effect of hemiplegia on bone mass and soft tissue body composition. Acta Neurol Scand. 1989; 79(2):155-9. DOI: 10.1111/j.1600-0404.1989.tb03729.x. View

14.

Slemenda C, Longcope C, Peacock M, Hui S, JOHNSTON C . Sex steroids, bone mass, and bone loss. A prospective study of pre-, peri-, and postmenopausal women. J Clin Invest. 1996; 97(1):14-21. PMC: 507057. DOI: 10.1172/JCI118382. View

15.

Melton 3rd L, Ilstrup D, Riggs B, Beckenbaugh R . Fifty-year trend in hip fracture incidence. Clin Orthop Relat Res. 1982; (162):144-9. View

16.

Overgaard K, Hansen M, Jensen S, Christiansen C . Effect of salcatonin given intranasally on bone mass and fracture rates in established osteoporosis: a dose-response study. BMJ. 1992; 305(6853):556-61. PMC: 1883290. DOI: 10.1136/bmj.305.6853.556. View

17.

Cooper C, Campion G, Melton 3rd L . Hip fractures in the elderly: a world-wide projection. Osteoporos Int. 1992; 2(6):285-9. DOI: 10.1007/BF01623184. View

18.

Geusens P, Dequeker J, Verstraeten A, Nijs J, van Holsbeeck M . Bone mineral content, cortical thickness and fracture rate in osteoporotic women after withdrawal of treatment with nandrolone decanoate, 1-alpha hydroxyvitamin D3, or intermittent calcium infusions. Maturitas. 1986; 8(4):281-9. DOI: 10.1016/0378-5122(86)90036-8. View

19.

Kanis J . Assessment of fracture risk and its application to screening for postmenopausal osteoporosis: synopsis of a WHO report. WHO Study Group. Osteoporos Int. 1994; 4(6):368-81. DOI: 10.1007/BF01622200. View

20.

Cummings S, Black D, Rubin S . Lifetime risks of hip, Colles', or vertebral fracture and coronary heart disease among white postmenopausal women. Arch Intern Med. 1989; 149(11):2445-8. View